Ginkgo Bioworks (NYSE:DNA) Insider Sells $84,135.00 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) insider Steven Coen sold 5,609 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total value of $84,135.00. Following the sale, the insider owned 5,503 shares in the company, valued at approximately $82,545. This trade represents a 50.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Ginkgo Bioworks Stock Performance

Shares of NYSE:DNA opened at $16.14 on Friday. The business’s fifty day moving average price is $12.35 and its two-hundred day moving average price is $9.76. The stock has a market cap of $955.43 million, a PE ratio of -2.75 and a beta of 1.54. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $16.85.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%.The company had revenue of $49.60 million for the quarter, compared to analyst estimates of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Saturday, September 27th. BTIG Research increased their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research note on Monday, August 25th. Finally, Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research note on Friday, August 8th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Ginkgo Bioworks presently has a consensus rating of “Reduce” and a consensus target price of $9.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Shay Capital LLC raised its position in shares of Ginkgo Bioworks by 6.2% in the 2nd quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock worth $218,000 after buying an additional 1,124 shares during the period. US Bancorp DE raised its position in shares of Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company’s stock worth $36,000 after buying an additional 1,911 shares during the period. California State Teachers Retirement System raised its position in shares of Ginkgo Bioworks by 10.0% in the 2nd quarter. California State Teachers Retirement System now owns 26,674 shares of the company’s stock worth $300,000 after buying an additional 2,426 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Ginkgo Bioworks in the 2nd quarter worth $29,000. Finally, Bank of New York Mellon Corp raised its position in shares of Ginkgo Bioworks by 14.4% in the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company’s stock worth $150,000 after buying an additional 3,331 shares during the period. 78.63% of the stock is owned by hedge funds and other institutional investors.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.